ArticleAnnals of clinical and translational neurology2019
Prolonged-release melatonin in patients with idiopathic REM sleep behavior disorder.
Article in Annals of clinical and translational neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Management of REM sleep behavior disorder: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2023Pooled it
- Effect of melatonin supplementation on sleep quality: a systematic review and meta-analysis of randomized controlled trials.Journal of neurology · 2022Pooled it
- Pharmacological Interventions for REM Sleep Behavior Disorder in Parkinson's Disease: A Systematic Review.Frontiers in aging neuroscience · 2021Pooled it
- Comparative efficacy of prolonged-release melatonin versus clonazepam for isolated rapid eye movement sleep behavior disorder.Sleep & breathing = Schlaf & Atmung · 2023Trial
- Melatonin for rapid eye movement sleep behavior disorder in Parkinson's disease: A randomised controlled trial.Movement disorders : official journal of the Movement Disorder Society · 2020Trial
- Clinical features, plasma neurotransmitter levels and plasma neurohormone levels among patients with early-stage Parkinson's disease with sleep disorders.Cell communication and signaling : CCS · 2025Article
- Validation of the RBD Symptom Severity Scale in the North American Prodromal Synucleinopathy Consortium.Neurology · 2024Article
- REM sleep behavior disorder: update on diagnosis and management.Arquivos de neuro-psiquiatria · 2023Article
- REM Behavior Disorder: Implications for PD Therapeutics.Current neurology and neuroscience reports · 2023Review
- Melatonin as a Chronobiotic/Cytoprotective Agent in REM Sleep Behavior Disorder.Brain sciences · 2023Review
- Neuroprotective effects of melatonin in neurodegenerative and autoimmune central nervous system diseases.Encephalitis (Seoul, Korea) · 2023Review
- Article
- Use of Melatonin and/on Ramelteon for the Treatment of Insomnia in Older Adults: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2022Review
- A critical review of the pharmacological treatment of REM sleep behavior disorder in adults: time for more and larger randomized placebo-controlled trials.Journal of neurology · 2022Review
- Emotional and Environmental Factors Aggravating Dream Enactment Behaviors in Patients with Isolated REM Sleep Behavior Disorder.Nature and science of sleep · 2022Article
- Management of Sleep Disturbances in Parkinson's Disease.Journal of Parkinson's disease · 2022Review
- Current Treatment Options for REM Sleep Behaviour Disorder.Journal of personalized medicine · 2021Review
- Sleep Disturbance, Sleep Disorders and Co-Morbidities in the Care of the Older Person.Medical sciences (Basel, Switzerland) · 2021Review
- Dream enactment behavior: review for the clinician.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2020Article
- Sleep Issues in Parkinson's Disease and Their Management.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Review
Corrections and comments
- Erratum issued
- Erratum issued
Authors and funding
13 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe investigated the effects of prolonged-release melatonin (PRM) on idiopathic rapid eye movement (REM) sleep behavior disorder (iRBD).
methodsIn this 4-week, randomized, double-blind, placebo-controlled pilot study, 30 participants with polysomnography-confirmed iRBD were assigned to receive PRM 2 mg per day, PRM 6 mg per day, or placebo. Medication was administered orally 30 min before bedtime. Primary outcomes included scores from the Clinical Global Impression-Improvement (CGI-I) and the Korean version of the RBD questionnaire-Hong Kong (RBDQ-KR). The secondary outcomes included RBDQ-KR factor 1 and factor 2 subscores, the Pittsburgh Sleep Quality Index score, the Epworth Sleepiness Scale score, the Short Form Health Survey version 2 score, and the frequency of dream-enacting behaviors assessed using a sleep diary.
resultsAfter 4 weeks, there were no differences in the proportions of patients with a CGI-I score of much improved or very much improved among the study groups. In addition, RBDQ-KR scores and secondary outcomes were not improved in all groups at 4 weeks, and there were no differences between the groups.
conclusionOur findings suggest that PRM may not be effective in treating RBD-related symptoms within the dose range used in this study. Further studies using doses higher than 6 mg per day are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.